Your browser doesn't support javascript.
loading
SARS-CoV-2-specific ELISA development.
Roy, Vicky; Fischinger, Stephanie; Atyeo, Caroline; Slein, Matthew; Loos, Carolin; Balazs, Alejandro; Luedemann, Corinne; Astudillo, Michael Gerino; Yang, Diane; Wesemann, Duane R; Charles, Richelle; Lafrate, A John; Feldman, Jared; Hauser, Blake; Caradonna, Tim; Miller, Tyler E; Murali, Mandakolathur R; Baden, Lindsey; Nilles, Eric; Ryan, Edward; Lauffenburger, Douglas; Beltran, Wilfredo Garcia; Alter, Galit.
Afiliación
  • Roy V; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Atyeo C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Slein M; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Loos C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America; Massachusetts Institute of Technology, Cambridge, MA 02139, United States of America.
  • Balazs A; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Luedemann C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Astudillo MG; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, United States of America.
  • Yang D; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, United States of America.
  • Wesemann DR; Brigham and Women's Hospital, Boston, MA 02115, United States of America.
  • Charles R; Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, United States of America.
  • Lafrate AJ; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, United States of America.
  • Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Hauser B; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Caradonna T; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.
  • Miller TE; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, United States of America.
  • Murali MR; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, United States of America.
  • Baden L; Brigham and Women's Hospital, Boston, MA 02115, United States of America.
  • Nilles E; Brigham and Women's Hospital, Boston, MA 02115, United States of America.
  • Ryan E; Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, United States of America.
  • Lauffenburger D; Massachusetts Institute of Technology, Cambridge, MA 02139, United States of America.
  • Beltran WG; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, United States of America.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America. Electronic address: galter@partners.org.
J Immunol Methods ; 484-485: 112832, 2020.
Article en En | MEDLINE | ID: mdl-32780998
ABSTRACT
Critical to managing the spread of COVID-19 is the ability to diagnose infection and define the acquired immune response across the population. While genomic tests for the novel Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests able to define exposure and infection beyond this short window of detectable viral replication are urgently needed. Following infection, antibodies are generated within days, providing a durable read-out and archive of exposure and infection. Several antibody tests have emerged to diagnose SARS-CoV-2. Here we report on a qualified quantitative ELISA assay that displays all the necessary characteristics for high-throughput sample analysis. Collectively, this test offers a quantitative opportunity to define both exposure and levels of immunity to SARS-CoV-2.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía Viral / Ensayo de Inmunoadsorción Enzimática / Infecciones por Coronavirus / Técnicas de Laboratorio Clínico / Betacoronavirus Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Immunol Methods Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía Viral / Ensayo de Inmunoadsorción Enzimática / Infecciones por Coronavirus / Técnicas de Laboratorio Clínico / Betacoronavirus Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Immunol Methods Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos